Inhibition by Tranilast of the Cytokine-Induced Expression of Chemokines and the Adhesion Molecule VCAM-1 in Human Corneal Fibroblasts

Abstract

Inhibition by tranilast of the cytokine-induced expression of eotaxin-1, TARC, and VCAM-1 in human corneal fibroblasts suggests that this drug might prove effective for treatment of the corneal manifestations of ocular allergic inflammation by targeting corneal fibroblasts directly.

Long-term Follow-up After Lamellar Keratoplasty in a Patient With Bilateral Idiopathic Corneal Keloid

“…9 The present authors recently reported that tranilast inhibited the expression of chemokines and adhesion molecules by corneal fibroblasts. 10 In the present case, topical tranilast treatment resulted in a gradual reduction in the size and protuberance of the corneal lesion in the right eye. This report describes the treatment outcome in a single patient, and further research is warranted to assess the effect of tranilast on corneal keloid in larger patient samples.…”

Tranilast reduces serum IL-6 and IL-13 and protects against thioacetamide-induced acute liver injury and hepatic encephalopathy

“…Tranilast has been reported to attenuate the pro-inflammatory activity of human monocytes (Capper et al, 2000), to suppress the production of various inflammatory cytokines and chemokines and to inhibit the cytokine-induced secretion of IL-6 in various cell types (Spiecker et al, 2002;Adachi et al, 2010).…”

“…It has also been used for the treatment of skin keloid and has been reported to protect against Schistosoma mansoni-induced liver fibrosis (Adachi et al, 2010;Said et al, 2012). Tranilast has been reported to inhibit the production or release of lipid mediators and cytokines from inflammatory cells and macrophages (Springer, 1990).…”

Tranilast: A review of its therapeutic applications

“…In addition, it also inhibits the surface expression of VCAM-1 in fibroblasts [19,24], expression of ICAM-1 from monocytes [25], release of IL-2 and IL-1␤ from monocytes and macrophages [26], release of TGF-␤1 from fibroblasts [17,26] also from mast cells and basophils [27], MMP-2 and -9 production from fibroblasts and neutrophils [28,29] as well as INF-␥ and TNF-␣ production [7]. Furthermore, the expression of HLA-DR and -DQ antigens on macrophages was significantly suppressed by treatment with tranilast [30].…”

“…Moreover, in a pilot study on 52 patients using 0.5% tranilast eye drops to investigate intraocular pressure and bleb formation after glaucoma filtering surgery, satisfactory results were observed and there were no side effects on eye vision [134]. Other potential applications for the treatment of eye conditions, include inhibiting retinal angiogenesis [129], ocular allergic inflammation [24], and posterior capsule opacification [140]. Now a phase III trial is evaluating the usefulness of tranilast for pterygium [6,141].…”